9 4
VOLUME 43 | NUMBER 12 | DECEMBER 2011 Nature GeNetics A r t i c l e s from the 1000 Genomes Project and any other available diseasespecific resequencing data. The 1000 Genomes Project pilot CEU low-coverage whole-genome-sequencing dataset captures 95% of the variants of minor allele frequency (MAF) = 0.05, and although it is underpowered to comprehensively detect variants of rarer allele frequency, the dataset still identifies 60% of variants of MAF = 0.02 and 30% of variants of MAF = 0.01 (ref. 11). The Immunochip Consortium selected 186 distinct loci containing markers reaching genome-wide significance (P < 5 × 10 −8 ) from 12 diseases (autoimmune thyroid disease, ankylosing spondylitis, Crohn's disease, celiac disease, IgA deficiency, multiple sclerosis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes and ulcerative colitis). We submitted all sample variants from the 1000 Genomes Project lowcoverage pilot CEU population 11 (September 2009 release) that were in 0.1-cM (HapMap3 CEU) recombination blocks around each GWAS region lead marker for array design. We did not apply any filtering on correlated variants (linkage disequilibrium (LD)). Further case and control regional resequencing data were submitted by several groups (Online Methods and Supplementary Note), as well as a small amount of investigatorspecific undisclosed content, including GWAS results of intermediate significance.
Most GWAS were performed using common SNPs (typically with MAF > 5%) further selected for low inter-marker correlation and/or even genomic spacing. In contrast to GWAS, the Immunochip Consortium represents an opportunity to in depth and comprehensively dissect the architecture of both rare and common genetic variation at immunobiologically relevant genomic regions in human diseases. Because of the presence of the majority of the polymorphic genetic variants from the 1000 Genomes Project pilot CEU dataset (as well as additional resequencing at some loci) in our final Immunochip dataset, the true causal variants at many risk loci may have been directly genotyped and analyzed.
RESULTS

Overview of the study design
We submitted a total of 207,728 variants for Immunochip assay design, and 196,524 variants passed manufacturing quality control at Illumina. After extensive and stringent data quality control (Online Methods), we analyzed a near-complete dataset (overall, there were only 0.008% missing genotype calls) comprising 12,041 cases with celiac disease, 12,228 controls (from seven geographic regions; Table 1 ) and 139,553 polymorphic (defined here as at least two observed genotype groups) markers. We assayed 634 biallelic SNPs in duplicate; at these SNPs, we observed 189 of the 15,384,884 (0.0012%) genotype calls to be discordant. Considering the intended 207,728 variants submitted for design and an observed ~9.1% non-polymorphic rate in our data after quality control filtering, we estimated that we had high quality genotype data on ~74% of the complete set of the 1000 Genomes Project pilot CEU true polymorphic variants at the finemapped regions.
We observed that 36 of the 183 non-HLA immune-mediated disease loci selected for dense 1000-Genomes-based genotyping using the Immunochip reached genome-wide significance (P < 5 × 10 −8 ) for celiac disease in either the current study or in our previous GWAS 5 (the summary association statistics for all markers are available in T1DBase (see URLs)). All variants reaching genome-wide significance were common (MAF > 5%). We also observed marked enrichment for celiac disease association signals of intermediate significance (for example, rs6691768, at the NFIA locus, P = 5.3 × 10 −8 ) at a proportion of the remaining 147 densely genotyped non-celiac autoimmune disease regions ( Supplementary Fig. 1 ). Variants from three densely genotyped regions selected on Immunochip for a non-immune-mediated trait (bipolar disorder) showed no excess of association signals ( Supplementary Fig. 1 ). HCFC1, TMEM187, IRAK1  UBE2L3,YDJC  ICOSLG  UBASH3A  PTPN2   ZFP36L1  SH2B3, ATXN2  ETS1  TREH, DDX6   ZMIZ1   PVT1  ELMO1  TAGAP  OLIG3, TNFAIP3  PTPRK  BACH2  IRF4  KIAA1109, ADAD1, IL2, IL21  LPP  SCHIP1, IL12A  ARHGAP31  CCR1-3, LTF  CCR4, GLB1  CD28, CTLA4, ICOS  STAT4  UBE2E3, ITGA4  IL18R1, IL18RAP  PLEK, FBX048  PUS10  C1orf106  RGS1  FASLG, TNFSF18  RUNX3  C1orf93, MMEL1, TTC34 PFKFB3, PRKCQ POU2AF1 and others SOCS1, PRM1, PRM2 CIITA and others CLK3 and others Figure 1 Manhattan plot of association statistics for previously known and newly discovered celiac disease risk loci. Newly discovered loci are indicated in blue; loci with multiple signals are shown in a gray highlighted box. The significance threshold used was P = 5 × 10 −8 .
A r t i c l e s 
A r t i c l e s
We identified 13 new celiac risk loci (P < 5 × 10 −8 ; Fig. 1 , Table 2 and Supplementary Fig. 2 ), 10 of which were immune-mediated disease loci selected for dense 1000-Genomes-based genotyping on the Immunochip. Several of these new loci were reported at lesser significance levels in our previous studies 5, 9 , and almost all of these loci have been reported in at least one other immune-mediated disease. These new loci, along with the HLA loci, bring the total number of reported (in the current and a previous study 5 , which had an 2) . The most strongly associated variant for a given signal is shown in bold, and further variants with r 2 > 0.90 (calculated from the 24,269-sample Immunochip dataset) are shown with normal weight. At each locus, the first signal is shown in blue, second is shown in red and third is shown in green. Squares indicate markers present in our previous celiac disease GWAS dataset after applying quality control filters (Illumina Hap550) 5 .
1 1 9 8 VOLUME 43 | NUMBER 12 | DECEMBER 2011 Nature GeNetics A r t i c l e s overlapping but slightly different sample set) genome-wide significant celiac disease loci to 40. Most of these loci contain candidate genes of immunological function, which is consistent with our previous findings at celiac disease loci [3] [4] [5] . The median of the effect sizes (odds ratios (ORs) and inverting protective effects) for the most significant marker per locus was 1.155 (range 1.124-1.360) for the top signals from 26 non-HLA loci measured using Illumina Hap300 and Hap550 LD-pruned tag SNPs in our 2010 celiac disease GWAS 5 and was 1.166 (range 1.087-1.408) for the corresponding most significant marker (for the same signal) per locus in the current high-density fine-mapping Immunochip data set (Wilcoxon test P = 0.75; Supplementary Table 1 ). Although we observed no difference in the effect sizes between the GWAS lead SNPs and the subsequent fine-mapped signals, we note that the resequencing of the cases in the current Immunochip dataset is limited (see the Discussion section).
In all, we report 57 independent celiac disease association signals ( Table 2 ) from 39 separate loci, of which 18 (32%) were not efficiently (r 2 > 0.9; Supplementary Table 2 ) tagged by our previous GWAS 5 (Illumina Hap550 dataset after quality control filtering) markers.
Multiple independent common and rare variant signals
In contrast to most GWAS chips, the Immunochip contains a substantial proportion of polymorphic variants of low MAF. Of 139,553 variants in our 11,837 controls of European ancestry, 24,661 variants are low frequency (defined 11 as MAF = 5-0.5%) and a further 22,941 variants are rare (MAF < 0.5%). We investigated the possibility of the existence of multiple independently associated variants (of any allele frequency) at each locus using stepwise logistic regression conditioning on the most significant variant at the locus (Online Methods and Supplementary Table 3 ). This analysis is sensitive to genotype miscalling and missing data 12 , hence our use of extremely rigorous quality control measures for the dataset and manual inspection of genotype clusters for all reported markers.
We observed two or more independent signals at 13 of the 36 high-density genotyped non-HLA loci (Fig. 2) . Four of these loci each had three independent signals (STAT4, the chromosome 3 CCR region, IL12A and SOCS1-PRM1-PRM2; Table 2 ). We observed low frequency and/or rare variant signals at four separate loci (RGS1, CD28-CTLA4-ICOS, SOCS1-PRM1-PRM2 and PTPN2). Notably, we saw the strongest effect (OR = 1.70) at the rare variant imm_16_ 11281298 (at the SOCS1-PRM1-PRM2 locus) with genotype counts (AA/AG/GG) of 1/136/11,904 (MAF 0.57%) in all cases with celiac disease and 0/91/12,136 (MAF 0.37%) in all controls (the detailed genotype count and allele frequency data for the top signals by collection are shown in Supplementary Table 4) .
We next performed haplotype analysis on all loci with multiple independent signals to investigate whether the multiple signals were a result of multiple causal effects or a single effect best tagged by several variants. For all but one locus (PTPN2), the haplotype association test results (data not shown) were of similar significance to those from the single SNP association tests, suggesting that for each signal, we genotyped either the causal variant or markers very strongly correlated with it. These findings contrast with those from a recent resequencing study 13 , probably because of the much greater variant density of our study. However, at the PTPN2 locus, the imm_18_12833137(T) + ccc-18-12847758-G-A(G) haplotype was considerably more strongly associated with disease (P = 4.8 × 10 −14 , OR = 0.84) than either SNP alone (imm_18_12833137, P = 1.9 × 10 −10 and ccc-18-12847758-G-A, P = 0.0008).
At the SOCS1 locus, the third independent signal, imm_16_ 11292457, showed association after conditioning on the two other signals (P = 2.0 × 10 −4 ) but not in the single-SNP non-conditioned association analysis (P = 0.15). Further inspection identified the protective imm_16_11292457(A) allele to be correlated (in LD) with the risk (A) allele of the first signal, imm_16_11268703; thus, although there are indeed three independent signals, the effect of the third signal is only seen after conditioning on the first. A similar statistical effect (Simpson's paradox) was recently shown at a Parkinson's disease locus 14 .
Fine mapping to localize causal signals GWAS signals are typically reported within relatively large LD blocks. We tested whether our much denser genotyping strategy would allow finer-scale localization and the pinpointing of association signals. We found that markers strongly correlated (r 2 > 0.9) with the most significant independent variant clustered together and defined regions that are a median of 12.5 times smaller than the relevant HapMap3 CEU 0.1-cM LD blocks (Table 2, Fig. 2 and Supplementary Fig. 2) . Localization was highly successful for some regions (for example, PTPRK and TAGAP) but was not possible at others (for example, IL2-IL21). At many loci, the localized regions comprised only a handful of markers in close physical proximity to each other.
Considering the 36 loci genotyped at high density, we localized 29 of the total 54 independent non-HLA signals to a single gene ( Table 2 and Supplementary Fig. 2) . We identified all markers strongly correlated (r 2 > 0.9) with the independent non-HLA variants reported in our analyses ( Table 2) , and using functional annotation (Supplementary Table 2) , identified only a handful of markers in exonic regions, of which three are protein-altering variants (the nonsynonymous SNPs imm_1_2516606 (MMEL1), imm_12_110368991 (SH2B3) and 1kg_X_152937386 (IRAK1)). In contrast, a number of signals appeared to be more finely localized around the transcription start site of specific genes (which we defined as the first exon and 10 kb 5′ of the first exon), including signals at RUNX3, RGS1, ETS1, TAGAP and ZFP36L1, and around the 3′ untranslated region (UTR) (and 10 kb 3′), including signals at IRF4, PTPRK and ICOSLG.
We saw overlap between multiple independent signal regions at some loci (Fig. 2) , suggesting that causal variants might be functioning through a shared mechanism, for example, within a 2-kb region of the PTPRK 3′ UTR, within an 11-kb region 5′ of IL12A or within a 28-kb region of TNFAIP3. In contrast, we observed multiple independent signals that spread across the three immune genes of the CD28-CTLA4-ICOS region.
DISCUSSION
We show that fine mapping of GWAS regions using dense resequencing data, for example, from the 1000 Genomes Project (as we used here), is feasible and generates substantial additional information at many loci. We identify a complex architecture of multiple common and rare genetic risk variants for around one-third of the now 40 confirmed celiac disease loci. The design of our study allowed us to find many more complex regions than the ~10% with multiple signals seen in our previous study 5 and a recent large GWAS for human height 15 . It seems probable that if larger sample sizes than those used in the current study were to be tested, additional loci might be shown to have a similarly rich architecture with multiple risk variants. Multiple independent risk signals for celiac disease have also long been known to exist in the HLA region 16 . Our success in identifying multiple risk signals in celiac disease might be partly a result of the extensive selective pressures for haplotypic diversity that have taken place at immune gene loci 17 . Previous studies reported independently associated common and rare variants at individual loci for a A r t i c l e s handful of phenotypes, for example, fetal hemoglobin 13 , sick sinus syndrome 18 , Crohn's disease 19 and hypertriglyceridemia 20 . To the best of our knowledge, this is the first study to have comprehensively surveyed the genetic architecture of all known risk loci for a trait.
In part, our identification of rare variants at risk regions relies on the prior discovery of a genome-wide significant common variant association signal at each locus. This then permits a per-locus correction rather than a genome-wide multiple-testing correction when searching for additional independent association signals. Only particularly strong rare variant signals would, on their own, generate significance levels reaching the genome-wide threshold typically used in GWAS (P < 5 × 10 −8 ). Alternative methods, such as collapsing rare variant signals across a gene or functional categories of genes, have therefore been suggested as approaches to this problem 21 . Although a rare variant may occur on a recent haplotypic background and thus show LD at a substantially longer range than common variants, we deliberately restricted our search to around the common-variant LD blocks because to do otherwise would have incurred a considerably greater penalty from multiple testing. Therefore, although our study provides considerable support for exome and whole-genome sequencing efforts aimed at identifying rare risk variants (and those not necessarily restricted to GWAS loci) in common complex diseases, it further highlights the statistical challenges of establishing associations for rare variants.
We used a dense genotyping strategy and a stepwise conditional association analysis but did not identify any rare highly penetrant variants that might explain the genome-wide significant common SNP signals at any of the 39 loci. Our study does have limitations in this regard, particularly: (i) the restriction of the analysis to 0.1-cM LD blocks; (ii) the limited control resequencing sample size of the 1000 Genomes Project pilot CEU dataset; (iii) the limited case resequencing sample size; and (iv) case resequencing being limited to three loci for celiac disease and to selected loci for other immune diseases. We observed a weak trend toward a lower MAF (P = 0.042, Wilcoxon test; Supplementary Table 1 ) for the best fine-mapping SNP from the Immunochip analysis compared to the lead SNP from our 2010 tag SNP GWAS (determined by measuring the MAF in a subset of samples genotyped in both datasets). One signal showed a substantially higher MAF (>25% change) using fine mapping and four signals showed a substantially lower MAF using fine mapping (Supplementary Table 1) , however, all fine-mapping variants corresponding to the lead GWAS SNPs remained common (MAF > 0.10). We suggest that these changes in the MAFs of the lead GWAS SNPs using fine mapping simply reflect a more precise measurement of common frequency risk haplotypes. Although we cannot exclude the possibility that a single high-penetrance lower-frequency variant explains most of the association signal at a locus, especially without more comprehensive resequencing of the cases, we found no evidence to support this possibility in the current fine-mapping analysis. Similarly, although our stepwise selection procedure cannot robustly refute the 'synthetic association' hypothesis-in particular, that a combination of multiple rare variants jointly explains the association signal 22 -we have so far not observed any evidence supporting this possibility.
We identified 13 new loci for celiac disease at genome-wide significance, most of which have been reported previously at lesser significance levels or in another immune-mediated disease. The Illumina Hap550 chip (used in our 2010 GWAS) would have detected 10 of the 13 new loci and, in total, 39 of the 57 independent non-HLA signals that we report here. A current genotyping platform, the Illumina Omni2.5 chip, would have detected 12 of the 13 new loci and, in total, 50 of the 57 independent non-HLA signals that we report here.
However, neither of these chips would have provided the finer-scale localization of the Immunochip. The 13 new loci contain many candidate genes with an immunological function (P = 0.0002 for enrichment of the Gene Ontology term 'immune system process' 23 ), which is in line with expectations based on our previous studies. We also found evidence suggesting that substantial additional signals exist at other immune-mediated disease loci that are below the genome-wide significance threshold applied to the current dataset. It is a point of debate whether such strict (P < 5 × 10 −8 ) criteria should apply; for example, an analyst might apply a higher Bayesian prior at a locus already reported in another immune-mediated disease. Alternatively, an Immunochip-wide P value with a Bonferroni correction for independent SNPs, as was used recently in the Cardiochip custom genotyping project 24 , of P < 1.9 × 10 −6 (Online Methods) would yield 16 new celiac disease loci in addition to the 13 we identified here. These 16 loci also mostly contain immune system genes. An analysis of these signals of intermediate significance would gain substantial additional power in a meta-analysis across the several hundred thousand samples from multiple immune-mediated disease collections currently being run on the Immunochip.
We found that our previous GWAS using tag SNPs gave very similar estimates of effect size as our current fine-mapping experiment (Supplementary Table 1) , which is in contrast to a simulation study that suggested that GWAS markers often underestimate risk 14 . However, we found substantial evidence for multiple additional signals at known loci and report many new loci. In individuals of European ancestry, the 39 non-HLA loci explain 13.7% of the genetic variance of celiac disease (HLA variants account for a further ~40%). We also show a long list of effects of weaker significance, which will explain substantial additional heritability.
Only one of the variants reported here was discovered in a diseasespecific resequencing study: ccc-18-12847758-G-A (rs62097857), a marker identified by the WTCCC's resequencing of cases with Crohn's disease and controls (Supplementary Note) and that is also present in the Watson genome. We submitted for Immunochip analysis ~4,000 variants from high-throughput resequencing of pools of 80 cases with celiac disease for extended genomic regions at three loci (RGS1, IL12A and IL2-IL21; Supplementary Note). These loci did not contribute any signals in addition to those obtained from the 1000 Genomes Project pilot CEU variants, although they did increase the number of variants correlated with each signal (that is, the set of markers that probably contains the causal variant(s)) and more precisely define the boundaries of the signal localization. We note that larger-scale resequencing of cases (for example, using many hundreds of samples) would identify a spectrum containing more rare variants than the current study, and this method has previously been used with success at selected genes and phenotypes.
The possibility of performing fine-scale mapping of GWAS regions using, for example, 1000 Genomes Project data, has been discussed as a natural follow-up strategy for such studies 25, 26 and has been used recently to identify risk variants in APOL1 in African-Americans with renal disease 27 . To our knowledge, our current report is the first to test such a strategy on a large scale in a complex disease. At multiple regions, we were able to refine the signal to a handful of variants over a few kb or tens of kb, although some regions (for example, IL2-IL21) were resistant to this approach, presumably because of the presence of particularly strong LD. Most GWAS report signals mapping to an LD block based on HapMap recombination rates (with a sample size of 60 families from the CEU dataset). In our data, where we have both much denser genotyping than GWAS chips (with a mean of 13.6× the genotyping density at celiac loci compared to the Illumina Hap550 chip) 1 2 0 0 VOLUME 43 | NUMBER 12 | DECEMBER 2011 Nature GeNetics A r t i c l e s and nearly 25,000 genotyped samples for the LD calculations, we are able to observe much finer-scale recombination and more precisely estimate the boundaries of no or minimal recombination intervals. Our findings are similar in terms of genotyping density and the resulting fine-mapped region size and lack of haplotype-specific effects to an earlier study of the IL2RA locus in type 1 diabetes 26 . At the majority of regions, we saw a tight block of highly correlated variants rather than a gradual decay of correlation (for example, see the plots for IL12A and PTPRK in Fig. 2) . At many loci, we defined a handful of likely candidates as the causal variant(s) to be taken forward to functional studies, although we may have missed candidate variants at some regions as a result of the sample size of the 1000 Genomes Project pilot CEU dataset (60 individuals), the status of the individuals in this dataset as controls and our estimate that ~25% of these variants were excluded from our final dataset. These variants could be assessed by imputation methods 28 , but our approach, particularly in regard to the more sensitive conditional regression analysis, has been to prefer the more accurate direct genotyping of all assayable variants. As much larger reference datasets based on whole-genome resequencing become available (for example, from the 1000 Genomes Project), these datasets could be imputed into our Immunochip dataset, including variants with substantially lower frequency 29 .
We also investigated whether our use of multiple ethnic subgroups within Europe (for example, Southern European Spanish compared to Northern European UK populations) or the relatively small Indian collection we used contributed to fine mapping and found that, in most instances, the same degree of localization was possible with just the UK collection alone (data not shown).
Our data suggest that most common risk variants function by influencing regulatory regions, which is consistent with variants previously reported in other immune-mediated diseases and in complex traits in general 11 . The exception is the SH2B3 non-synonymous SNP imm_12_110368991 (rs3184504) reported in our 2008 celiac GWAS 4 , which, even with fine mapping of 938 polymorphic variants from the SH2B3 region, remains the strongest signal at this locus, suggesting it may be the causal variant. The same variant has been associated with other immune diseases and a functional immune phenotype 5 . Notably, we observed a common ~980-bp intergenic deletion between IL2 and IL21 (DGV40686, accurately genotyped by Infinium assay with a control MAF = 7.3%) that correlated with the second independent signal at this region, although we have no evidence to suggest causality at this location.
Our fine-scale localization approach identified probable causal genes at multiple loci and at eight genes signals localized around the 5′ or 3′ regulatory regions. For example, at the THEMIS-PTPRK locus, two independently associated sets of variants cluster in the 3′ UTR of PTPRK (one, imm_6_128332892 (rs3190930), is located in a predicted binding site for the microRNA hsa-miR-1910). PTPRK, a TGF-β target gene, is involved in CD4 + T cell development, and a deletion mutation in PTPRK causes T helper cell deficiency in the LEC rat strain 30 . The signal at TAGAP is within a 4-kb region immediately 5′ of the transcription start site and presumably contains promoter elements. At ETS1, the signal comprises six variants overlapping the promoter and first exon of the T cell expressed isoform NM_001162422.1, and one of these variants (imm_11_127897147 (rs61907765)) has predicted regulatory potential and overlaps multiple transcription factor binding sites (UCSC GenomeBrowser ChipSeq and ESPERR tracks (see URLs); Supplementary Table 2 ). We observed similarly notable variants in regulatory regions of RUNX3 (imm_1_25165788 (rs11249212)) and RGS1 (imm_1_190807644 (rs1313292) and imm_1_190811418 (rs2984920)) ( Supplementary Table 2 ). A similar approach to identify the functional potential of risk variants was recently successfully used to define a causal variant in TNFAIP3 for systemic lupus erythematosus 31 . Although we localized signals at many loci, and although recent research suggests the causal gene is often located near the most strongly associated variant 15 , only more detailed functional studies (for example, transcription factor binding assays 31 and transcriptional activity assays of constructs with individual single nucleotide alterations at risk SNPs 32 ) will show precisely which gene variants might be causal.
We conclude that dense fine mapping of regions identified through GWAS can uncover a complex genetic architecture of independent common and rare variants and can often successfully localize risk variant signals to a small set of SNPs to be taken forward to functional assays. Denser fine-mapping studies using larger resequencing sample sizes from both cases and controls over broader regions might provide further resolution of GWAS signals.
URLs. Database of Genomic Variants, http://projects.tcag.ca/ variation/?source=hg18; T1Dbase, http://www.t1dbase.org; UCSC Genome Browser, http://genome.ucsc.edu/; ESPERR, http://www. bx.psu.edu/files/projects/esperr/; SIFT, http://sift.jcvi.org/; BioGPS, biogps.gnf.org; PreventCD consortium, www.preventceliacdisease. com; Wellcome Trust Case Control Consortium, http://www.wtccc. org.uk/; European Genome-Phenome Archive, http://www.ebi. ac.uk/ega/; R, http://www.r-project.org/.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
